Harmony Biosciences (NASDAQ:HRMY) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Harmony Biosciences (NASDAQ:HRMY) from a buy rating to a hold rating in a research report report published on Saturday.

Other analysts also recently issued reports about the stock. Bank of America cut their price objective on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $55.00 price target on shares of Harmony Biosciences in a research note on Wednesday. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective for the company. in a research report on Monday, February 23rd. Mizuho set a $50.00 price objective on Harmony Biosciences in a report on Thursday, February 19th. Finally, Truist Financial downgraded Harmony Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Harmony Biosciences has a consensus rating of “Hold” and a consensus price target of $42.67.

Harmony Biosciences Trading Down 1.8%

Shares of NASDAQ HRMY opened at $28.54 on Friday. The company has a market cap of $1.65 billion, a price-to-earnings ratio of 10.53, a price-to-earnings-growth ratio of 0.35 and a beta of 0.84. The stock’s 50 day simple moving average is $36.01 and its 200 day simple moving average is $34.06. The company has a current ratio of 3.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.17. Harmony Biosciences has a 12-month low of $25.52 and a 12-month high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. During the same period in the prior year, the business earned $0.85 earnings per share. Harmony Biosciences’s quarterly revenue was up 21.1% on a year-over-year basis. Equities research analysts expect that Harmony Biosciences will post 2.43 EPS for the current year.

Insider Activity at Harmony Biosciences

In related news, CFO Sandip Kapadia sold 20,961 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $35.92, for a total transaction of $752,919.12. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,640 shares of company stock valued at $1,932,256 over the last quarter. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Amundi raised its position in Harmony Biosciences by 115.6% in the first quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after acquiring an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after purchasing an additional 984 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Harmony Biosciences in the 1st quarter worth approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Harmony Biosciences by 53.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after purchasing an additional 33,058 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in Harmony Biosciences during the second quarter worth approximately $1,563,000. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences News Summary

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.